Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept

scientific article published on 25 July 2006

Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10067-006-0356-5
P698PubMed publication ID16865310

P2093author name stringD Patakas
P Argyropoulou
V Bagalas
I Kioumis
P2860cites workHuman leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 yearsQ38905579
Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximabQ40489366
Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapyQ40598694
Visceral leishmaniasis and HIV-1 co-infection in southern FranceQ40687984
Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategiesQ40833417
Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritisQ44494520
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanismQ67267340
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritisQ71160284
Granulomatous infections due to tumor necrosis factor blockade: correctionQ80867344
Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugsQ95810127
P433issue8
P921main subjectrheumatoid arthritisQ187255
visceral leishmaniasisQ2046113
P304page(s)1344-1345
P577publication date2006-07-25
P1433published inClinical RheumatologyQ15754927
P1476titleVisceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept
P478volume26

Reverse relations

cites work (P2860)
Q56771969Q56771969
Q61313261An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced byLeishmania major infection
Q93011826Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression
Q37306365Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe
Q34665258Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model
Q35219247New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.
Q40627316Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-γ production by spleen cells from human visceral leishmaniasis patients
Q40436057Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?
Q39529489Visceral leishmaniasis in immunosuppressed Caucasian patient